March 25, 2019
Eisai has launched a global PIII trial for its Alzheimer’s drug candidate BAN2401, the Japanese company said on March 22, just a day after it and its partner Biogen reported a big failure of aducanumab, another amyloid-targeting antibody. Topline data...read more